Methods comprising apoptosis inhibitors for the generation of transgenic pigs

Stem Cell Clinic
Patient Application
FAQ
Contact
Locations
News
Videos
Research
Patents
3D Culture/Scaffold
Administration
Differentiation
Expansion
Extraction/Preservation
Mobilization
Type
USE
 


Stem Cell Related Patent Number US5925548

Title:Modified receptors that continuously signal
Inventors:Beutler, Bruce A.; Dallas, TX, USA
Bazzoni, Flavia M.; Dallas, TX, USA
Summary:Described herein are novel constructs for stimulating the signaling in cells, and which are comprised of a cytokine receptor cytoplasmic domain linked to a multimerizing extracellular domain. The invention relates to chimeric polypeptides with engineered cell surface receptors that are active in the absence of the cytokine, hormone or molecule that normally activates the receptor, such that these receptors are engineered to form multimers at the cell surface. Further disclosed are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and in which the extracellular, multimerizing domain is derived from an erythropoietin receptor. Claims of the invention include strong cytotoxic effects which result from the transfection of such fusion protein constructs into cells. Also provided are properties of associated DNA, protein and cellular compositions, and methods of their production as well as therapeutic and experimental applications.
Abstract:Engineered cell surface receptors are described that are constitutively active in the absence of the cytokine, hormone or molecule that normally activates the receptor. Receptors that constitutively signal are generally created by engineering the receptor to form multimers at the cell surface. Disclosed are various DNA, protein and cellular compositions and methods of making and using such constitutively active receptors. Particular examples are fusion proteins in which the stem, transmembrane domain and cytoplasmic domain are derived from a TNF receptor, and the extracellular, multimerizing domain is derived from an erythropoietin receptor. Transfection of such fusion protein constructs into cells is shown to result in a strong cytotoxic effect.
US Patent Website:Click Here for Full Text of Patent
Title Number:US5925548
Application Number:US1996000762308
Date Filed:09/12/1996
Date Published:20/07/1999
Assignee:Board of Regents, The University of Texas System, Austin, TX, USA


 
Copyright © 2007 The Institute for Cellular Medicine  6/22/2021